Relmada Therapeutics, Inc.
RLMD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $46,176 | $54,807 | $113,322 | $90,622 |
| G&A Expenses | $37,716 | $48,895 | $47,926 | $35,082 |
| SG&A Expenses | $37,716 | $48,895 | $47,926 | $35,082 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1 | $0 |
| Operating Expenses | $83,891 | $103,702 | $161,249 | $125,703 |
| Operating Income | -$83,891 | -$103,702 | -$161,249 | -$125,703 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3,912 | $4,910 | $4,206 | -$48 |
| Pre-Tax Income | -$79,979 | -$98,792 | -$157,043 | -$125,752 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$79,979 | -$98,792 | -$157,043 | -$125,752 |
| % Margin | – | – | – | – |
| EPS | -2.65 | -3.28 | -5.3 | -7.16 |
| % Growth | 19.2% | 38.1% | 26% | – |
| EPS Diluted | -2.65 | -3.28 | -5.3 | -7.16 |
| Weighted Avg Shares Out | 30,164 | 30,099 | 29,629 | 17,553 |
| Weighted Avg Shares Out Dil | 30,164 | 30,099 | 29,629 | 17,553 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3,530 | $5,152 | $2,659 | $1,199 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $103,702 | $2 | $1 |
| EBITDA | -$83,891 | $4,910 | -$161,247 | -$125,702 |
| % Margin | – | – | – | – |